COMPANY INFO
NewLimit is a biotechnology research company founded in 2022 by Blake Byers, Brian Armstrong, and Jacob Kimmel. The company, headquartered in South San Francisco, California, has about 37 to 43 employees and focuses on developing epigenetic reprogramming therapies to extend human healthspan. Their website is https://www.newlimit.com.
NewLimit is a biotechnology research company founded in 2022 by Blake Byers, Brian Armstrong, and Jacob Kimmel. Headquartered in South San Francisco, California, NewLimit focuses on developing epigenetic reprogramming therapies aimed at extending human healthspan. With approximately 37 to 43 employees, NewLimit operates in the cutting-edge field of biotechnology, combining advances in genomics, machine learning, and cellular biology to pioneer new therapeutic strategies.
NewLimit has attracted significant attention in the life sciences and venture capital community due to its ambitious mission and accomplished founding team. Since its inception, NewLimit funding rounds have raised a total of $202.2 million across two rounds. The company’s funding strategy reflects a focus on breakthrough science and the application of artificial intelligence in medicine, while building partnerships with leading investors in technology and biotech. Notable milestones include a $40 million Series A to launch initial discovery programs and a subsequent $130 million Series B at a valuation of $810 million to advance clinical development and scale research capabilities. The combination of top-tier investors and rapid capital formation underscores investor confidence in NewLimit’s vision and long-term growth potential.
The Series B round provided $130 million in capital to accelerate the development of medicines to treat aging, leveraging AI and genomics. The funds will support pushing liver mRNA medicines into clinical trials and expanded research and development to extend healthy human life.
NewLimit’s Series A raised $40 million to support initial product development, focusing on extending human healthspan through epigenetic reprogramming and AI-enabled drug discovery. The investment established NewLimit’s foundational research efforts and operational growth.
Kleiner Perkins is a renowned venture capital firm backing entrepreneurs in enterprise, consumer, healthcare, and sustainability. As a key lead investor in NewLimit’s Series B and a participant in earlier rounds, Kleiner Perkins has played a critical role in NewLimit investment decisions and scaling the company’s research capabilities.
Founders Fund is a leading venture capital firm known for investing in innovative technology and biotech startups. As a lead investor in NewLimit’s Series A, Founders Fund brings strategic guidance and a broad network in future technology and healthcare.
Dimension Venture Partners participated in NewLimit’s Series A as a lead investor, providing capital and expertise in life sciences and deep technology, thereby supporting NewLimit’s ambitious research agenda.
Khosla Ventures is a high-profile venture capital firm investing in breakthrough technologies. Their involvement evidences confidence in NewLimit’s scientific approach and potential to impact human healthspan.
Nat Friedman is a distinguished angel investor and former CEO of GitHub. His participation as an investor in NewLimit funding rounds reflects strong belief in the founding team and the company’s vision for biotechnology innovation.
Daniel Gross is known for backing technologically transformative companies. As an investor, he supports NewLimit in its mission to combine AI and biology for therapeutic discoveries.
Elad Gil is a prominent entrepreneur and angel investor. He contributes both funding and strategic advice to accelerate NewLimit’s growth and R&D efforts.
Garry Tan, President & CEO of Y Combinator, invests in high-impact startups and helps connect NewLimit to top-tier entrepreneurial ecosystems and resources.
Patrick Collison, co-founder and CEO of Stripe, is a significant angel investor in NewLimit, offering capital and his expertise in scaling technology-driven companies.
Websets is a powerful natural language search and data enrichment tool that helps you discover comprehensive funding information for any company. Whether you're researching NewLimit funding rounds or exploring investment data for other companies, Websets provides detailed insights into funding history, investors, and financial milestones.
With Websets, you can access detailed funding profiles, investor information, and financial data through intuitive natural language queries. Sign up now to enhance your funding research capabilities.